Atali plant stabilization delays
Startup hiccups at Atali have impacted production plans; resolution expected by Q4 but may slip further, delaying revenue ramp-up.
high · management_commentaryAarti Pharmalabs Limited — Q3 FY26
Aarti Pharmalabs reported Q3 FY26 revenue of ₹5,425 crore, up 15% YoY, but EBITDA fell to ₹103 crore (down 10% YoY) and PAT dropped to ₹44 crore (down 41% YoY), reflecting margi...
bearish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
API business margin pressure and degrowth
API revenue declined YoY due to pricing pressure and slower customer off-take; recovery may take several quarters.
high · management_commentaryCDMO revenue concentration on few molecules
80% of CDMO sales come from 7-8 projects; failure of any key project could materially impact revenue.
medium · analyst_questionChina rebate withdrawal benefit may not fully materialize
While China's rebate withdrawal could boost pricing, locked-in contracts may limit near-term realization.
medium · data_observation